ClinicalTrials.gg

Program

BT-114143

A development code. Also written as “Low-dose BT-114143”, “BT-114143 Injection at low dose” and “BT-114143 Injection at Medium-dose”.

Its studies are mostly in Metrorrhagia, led by ScinnoHub Pharmaceutical.

Furthest: phase 2, since Jul 18, 20253 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ScinnoHub Pharmaceutical32 open or runningphase 2since Jul 18, 2025Jul 18, 2025Dec 31, 2026phase 2 · NCT07127042

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2025First study: phase 2 study in Total Knee ArthroplastyFirst studyNCT07127042 · 270 planned · China
  2. Aug 14, 20252 phase 1 studiesNCT07169214, NCT07169240

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Total Knee ArthroplastyNCT07127042

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07169240Healthy Subjects (HS) · China1CompletedApr 17, 202484
NCT07169214Metrorrhagia · China1RecruitingSep 23, 202539
NCT07127042Total Knee Arthroplasty · China2RecruitingDec 31, 2026270

How it is read

Names in the registry

  • “BT-114143”, 11 entries
  • “Low-dose BT-114143”, 1 entry
  • “BT-114143 Injection at low dose”, 1 entry
  • “BT-114143 Injection at Medium-dose”, 1 entry
  • “BT-114143 Injection at High-dose”, 1 entry

Codes read as this program: BT114143.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.